NASDAQ:PBM Psyence Biomedical Q4 2026 Earnings Report $2.89 +0.02 (+0.70%) Closing price 04:00 PM EasternExtended Trading$2.93 +0.04 (+1.35%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Psyence Biomedical EPS ResultsActual EPS-$0.41Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APsyence Biomedical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APsyence Biomedical Announcement DetailsQuarterQ4 2026Date6/22/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Psyence Biomedical Earnings HeadlinesPsyence Biomedical (NASDAQ:PBM) Shares Up 1% - Here's WhyJuly 10, 2026 | americanbankingnews.comPsyence BioMed to Engage U.S. Stakeholders on Psychedelic Medicine Research and Ibogaine Supply InitiativesMay 15, 2026 | quiverquant.comQThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 15 at 1:00 AM | Investors Alley (Ad)Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and ManufacturingMay 15, 2026 | globenewswire.comPsyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer PatientsApril 23, 2026 | quiverquant.comQPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderApril 23, 2026 | financialpost.comFSee More Psyence Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Psyence Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Psyence Biomedical and other key companies, straight to your email. Email Address About Psyence BiomedicalPsyence Biomedical (NASDAQ:PBM) engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.View Psyence Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)State Street (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
